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Background and Objective:	The	potential	benefit	of	using	hyaluronan	(HA)	in	
reconstructive	periodontal	surgery	is	still	a	matter	of	debate.	The	aim	of	the	present	
study	was	to	evaluate	the	effects	of	two	HA	formulations	on	human	oral	fibroblasts	
involved	in	soft	tissue	wound	healing/regeneration.
Material and Methods:	Metabolic,	 proliferative	 and	migratory	 abilities	 of	 primary	
human	palatal	and	gingival	 fibroblasts	were	examined	upon	HA	treatment.	To	un-
cover	 the	 mechanisms	 whereby	 HA	 influences	 cellular	 behavior,	 wound	 healing-	
related	gene	expression	and	activation	of	signaling	kinases	were	analyzed	by	qRT-	PCR	
and	immunoblotting,	respectively.
Results:	The	investigated	HA	formulations	maintained	the	viability	of	oral	fibroblasts	
and	increased	their	proliferative	and	migratory	abilities.	They	enhanced	expression	
of	genes	encoding	type	III	collagen	and	transforming	growth	factor-	β3,	characteristic	
of	scarless	wound	healing.	The	HAs	upregulated	the	expression	of	genes	encoding	
pro-	proliferative,	pro-	migratory,	and	pro-	inflammatory	factors,	with	only	a	moderate	
effect	on	the	latter	in	gingival	fibroblasts.	In	palatal	but	not	gingival	fibroblasts,	an	
indirect	effect	of	HA	on	the	expression	of	matrix	metalloproteinases	2	and	3	was	
detected,	 potentially	 exerted	 through	 induction	 of	 pro-	inflammatory	 cytokines.	
Finally,	our	data	pointed	on	Akt,	Erk1/2	and	p38	as	the	signaling	molecules	whereby	
the	HAs	exert	their	effects	on	oral	fibroblasts.
Conclusion:	Both	investigated	HA	formulations	are	biocompatible	and	enhance	the	
proliferative,	migratory	and	wound	healing	properties	of	cell	types	involved	in	soft	
tissue	wound	healing	following	regenerative	periodontal	surgery.	Our	data	further	
suggest	that	in	gingival	tissues,	the	HAs	are	not	likely	to	impair	the	healing	process	by	
prolonging	inflammation	or	causing	excessive	MMP	expression	at	the	repair	site.
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1  | INTRODUC TION
Hyaluronan	(HA)	is	a	naturally	occurring	non-	sulfated	glycosamino-
glycan	involved	in	maintaining	extracellular	matrix	(ECM)	resilience	
and	 tissue	hydration.	HA	 is	present	 in	various	body	 fluids	 such	as	
synovial	 fluid,	 serum,	 saliva,	 and	gingival	 crevicular	 fluid1-3	 as	well	
as	 in	 mineralized	 and	 non-	mineralized	 tissues,	 including	 the	 peri-
odontium.4	Higher	amounts	of	HA	are	detected	in	gingiva	and	peri-
odontal	ligament5	than	in	cementum6 and alveolar bone.7	Due	to	its	
hygroscopic	and	viscoelastic	properties	as	well	as	high	conservation	
among	species,	HA	has	been	utilized	in	a	number	of	biomedical	ap-
plications	in	dermatology,	ophthalmology,	osteoarthritis	treatment,	
oral	and	maxillofacial	surgery	as	well	as	in	various	tissue	engineering	
applications.8	Although	HA	is	 involved	in	many	different	biological	
processes	 during	 tissue	 repair	 and	 regeneration,	 detailed	 mecha-
nisms	of	action	especially	in	oral	soft	tissue	wound	healing	following	
periodontal	regenerative	procedures	remain	largely	uncovered.
During	 wound	 healing,	 HA	 exhibits	 differential	 effects	 based	
on	its	molecular	weight	(MW).9	 In	early	stages,	there	is	a	sharp	in-
crease	 in	 high	MW	 (>1000	kDa)	HA,	which	has	 the	 ability	 to	bind	
fibrinogen,	a	 reaction	 intrinsic	 to	clot	 formation.10	The	 initial	 large	
HA	polymer	 is	anti-	angiogenic	and	 immunosuppressive,	facilitating	
polymorphonuclear	leukocyte	access	to	the	wound	site	for	removal	
of	dead	tissue,	debris	and	bacteria.	Thereafter,	in	the	inflammatory	
stage,	HA	fragments	of	lower	MW	(<700	kDa)	accumulate	due	to	hy-
aluronidase	activity	or	oxidation.11	These	are	able	to	induce	produc-
tion	of	pro-	inflammatory	cytokines	such	as	tumor	necrosis	factor-	α 
(TNF-	α),	 interleukin-	1β	 (IL-	1β)	 and	 IL-	812	 as	well	 as	 angiogenesis.13 
In	periodontal	wound	healing	 in	particular,	HA	has	been	shown	to	
induce	 production	 of	 pro-	inflammatory	 cytokines	 by	 fibroblasts,	
keratinocytes,	cementoblasts,	and	osteoblasts,	which	promotes	the	
inflammatory	 response	 and	 consequently	 stimulates	 hyaluronan	
synthesis	by	endothelial	cells.14
The	wound	healing	process	 involves	a	number	of	events	 rigor-
ously	controlled	by	matrix	metalloproteinases	 (MMPs)	and	growth	
factors	 including	transforming	growth	factor-	β1	 (TGF-	β1),	platelet-	
derived	 growth	 factor	 (PDGF),	 fibroblast	 growth	 factor-	2	 (FGF-	2),	
and	epidermal	growth	factor	(EGF).15	MMPs	degrade	ECM	compo-
nents	 and	 elicit	 a	 pro-	inflammatory	 response,	 thus	 promoting	 cell	
migration	 during	 wound	 remodeling.16	 PDGF	 induces	 cellular	 re-
sponses	throughout	all	phases	of	 the	repair	process.17	TGF-	β1	has	
been	recognized	as	a	key	regulator	of	collagen	expression.18	FGF-	2	
plays	a	role	in	re-	epithelialization,	angiogenesis,	and	granulation	tis-
sue	formation	but	also	contributes	to	matrix	synthesis	and	remodel-
ing,	which	are	critical	for	the	wound	healing	process.19	Similarly,	EGF	
is	 a	 potent	 stimulator	 of	 epithelialization,	 angiogenesis,	 fibroblast	
proliferation,	and	survival.20
A	number	of	studies	describe	the	use	of	exogenous	HA	in	non-	
surgical	 and	 surgical	 periodontal	 therapy	with	 generally	 beneficial	
but	moderate	effects	on	surrogate	outcome	variables	of	periodontal	
inflammation,	ie,	bleeding	on	probing	and	residual	pocket	depth.21,22 
However,	only	few	studies	exist	on	the	use	of	HA	in	reconstructive	
periodontal	surgery.23-26	Before	such	clinical	studies	are	conducted,	
a	better	understanding	of	the	influence	of	HA	on	the	behavior	of	oral	
fibroblasts	involved	in	periodontal	regeneration	is	needed.	Thus,	the	
goal	of	the	present	study	was	to	 investigate	the	in	vitro	effects	of	
two	 commercially	 available	 HA	 preparations	 of	 non-	animal	 origin	
planned	 to	 be	 used	 in	 reconstructive	 periodontal	 surgery.	 The	 in-
fluence	of	the	two	HA	preparations	on	the	proliferative	and	migra-
tory	 abilities	 of	 primary	 human	palatal	 and	 gingival	 fibroblasts,	 as	
the	main	cell	 types	 involved	 in	soft	 tissue	regeneration	 in	 the	oral	
cavity,	was	investigated.	Furthermore,	we	studied	the	rapid	activa-
tion	of	signaling	proteins	elicited	by	the	two	HA	formulations.	We	
hypothesized	that	HA	stimulates	the	wound	healing	potential	of	oral	
fibroblasts	in	vitro	and	would	thus	contribute	to	soft	tissue	healing/
regeneration	following	reconstructive	periodontal	surgery.
2  | MATERIAL AND METHODS
2.1 | Cell culture and HA preparations
Primary	 human	 palatal	 (HPF)	 and	 gingival	 (HGF)	 fibroblasts	 were	
obtained	 from	 three	 donors	 each	 using	 tissue	 explant	 technique.	
Tissue	samples	harvested	from	either	subepithelial	palatal	connec-
tive	tissue	grafts	(for	obtaining	HPFs)	or	subepithelial	buccal	gingival	
tissues	 (for	 obtaining	HGFs)	were	 retrieved	 from	 systemically	 and	
periodontally	 healthy	 anonymous	 individuals	 below	30	years,	who	
had	 undergone	 periodontal	 surgery	 (eg,	 recession	 coverage	 using	
palatal	 subepithelial	 connective	 tissue	 grafts	 or	 crown	 lengthen-
ing)	 following	signed	 informed	consent	and	approval	by	the	Ethics	
Committee	of	the	University	of	Bern.	Each	donor	tissue	sample	was	
minced	 into	 1-	mm	 tissue	 explant	 pieces,	 which	 were	 then	 pipet-
ted	 into	a	25-	cm3	 tissue	culture	 flask	and	cultivated	 in	Dulbecco’s	
modified	 Eagle’s	 medium	 (DMEM;	 Invitrogen,	 Basel,	 Switzerland)	
supplemented	 with	 10%	 fetal	 calf	 serum	 (FCS;	 Invitrogen).	 Thus,	
each	of	the	HPF	and	HGF	strains	originating	from	individual	donors	
represents	a	mixture	of	 fibroblasts	 that	grew	of	multiple	explants.	
Fibroblasts	 that	had	not	undergone	more	 than	 five	passages	were	
starved	in	0.3%	FCS/DMEM	before	treatment	with	HA.
Hyaluronan	 was	 kindly	 provided	 by	 Regedent	 AG	 (Zurich,	
Switzerland)	in	two	formulations:	(a)	HA1	(hyaDENT),	a	native	non-	
cross-	linked	HA	with	MW	of	2500	kDa;	and	(b)	HA2	(hyaDENT	BG),	
a	 formulation	 containing	 complexes	 of	 butanediol	 diglycidyl	 ether	
(BDDE)	cross-	linked	1000	kDa-	HA	monomers	and	 the	above	non-	
cross-	linked	 form	 in	a	 ratio	of	8:1.	According	 to	 the	manufacturer,	
the	sizes	of	the	two	HAs	as	well	as	the	cross-	linking	ratio	are	neces-
sitated	by	the	production	process,	potential	of	current	technologies	
and	application	properties,	eg,	the	applied	cross-	linking	ratio	slows	
the	resorption	rate	of	HA2	while	creating	a	gel-	type	optimal	for	clin-
ical	application.
For	RNA	analyses,	cells	were	plated	at	3	×	104	cells/cm2	on	HA-	
coated	plates	for	24	hour.	For	protein	analyses,	6	hour	after	seeding	
at	the	same	density,	the	adherent	cells	were	starved	in	0.3%	FCS/
DMEM	 for	 18	hour	 and	 then	 treated	with	HA	 applied	 on	 the	 top	
for	30	minutes.	For	both	types	of	analyses,	HA	was	used	at	a	final	
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concentration	of	4	mg/mL	 in	0.3%FCS/DMEM.	This	 concentration	
was	 chosen	based	on	 (a)	 pilot	 experiments	 (data	not	 shown)	 com-
paring	4	mg/mL-	diluted	HAs	with	the	undiluted	commercial	prepara-
tions	and	(b)	the	assumption	that	each	of	the	HA	preparations	will	be	
naturally	diluted	by	patients’	blood	and	saliva	during	the	periodontal	
surgical	 procedure.	 In	 some	cases,	 cells	were	 treated	with	 recom-
binant	 IL-	1α,	 IL-	1β	 or	 TNF-	α	 protein	 (PeproTech,	 London,	 UK)	 for	
48	hours	before	RNA	extraction.
2.2 | Cell viability assay
Cell	 viability	 was	 assessed	 by	 the	 CellTiter-	Blue	 viability	 assay	
(Promega,	Madison,	WI,	 USA).	 After	 24	hour	 of	 starvation,	 cells	
were	 plated	 in	 triplicate	 at	 5	×	103	 cells/well	 on	 96-	well	 plates	
coated	with	HA	at	 the	 indicated	 concentrations	 (in	 the	 range	of	
0	 and	 4	mg/mL)	 prepared	 in	 0.3%FCS/DMEM.	 Two	 hours	 post-	
seeding,	 CellTiter-	Blue®	 Reagent	 (20	μL/well)	 was	 added	 to	 the	
cells	 for	 4	hour	 before	 recording	 fluorescence	 using	 a	 luminom-
eter	Infinite®	200	(Tecan,	Männedorf,	Switzerland).	Experimental	
values	 were	 normalized	 to	 the	 values	 of	 untreated	 cells	 (100%	
viability).	 Data	 represent	 means	±	SD	 from	 three	 independent	
experiments	performed	with	 three	different	cell	donors,	each	 in	
triplicates.
2.3 | Cell proliferation assay
Proliferation	 rates	 of	 HA-	treated	 HPF	 or	 HGF	 cells	 were	 deter-
mined	 using	 a	 5-	bromo-	20-	deoxyuridine	 (BrdU)	 incorporation	
assay	 (Roche,	 Basel,	 Switzerland)	 as	 described.27,28	 After	 24	hour	
of	starvation,	cells	were	plated	in	triplicate	at	2	×	103	cells/well	on	
96-	well	plates	coated	with	HA	at	a	final	concentration	of	4	mg/mL	
in	0.3%FCS/DMEM.	Cells	were	allowed	to	proliferate	for	0,	24,	48,	
72,	and	96	hour	before	 labeling	with	BrdU	for	2	hour.	BrdU	 incor-
poration	into	newly	synthesized	DNA	was	determined	according	to	
manufacturer’s	 instructions.	 Experimental	 values	were	 normalized	
to	the	values	of	untreated	cells	at	the	time	point	0.	Data	represent	
means	±	SD	 from	 three	 independent	 experiments	 performed	with	
three	different	cell	donors,	each	in	triplicates.
2.4 | Cell migration assay
Cell	migration	was	 assayed	 using	 transwell	 polycarbonate	mem-
brane	 inserts	 (Corning,	 Amsterdam,	 The	 Netherlands)	 as	 de-
scribed.27	After	24	hour	of	starvation,	5	×	104	cells	were	plated	in	
the	top	insert	chamber	in	serum-	free	DMEM.	The	lower	chamber	
was	coated	with	HA	at	a	 final	 concentration	of	4	mg/mL	 in	10%	
FCS/DMEM.	 Cells	 were	 allowed	 to	 migrate	 across	 the	 filter	 for	
18	hour	at	37°C	before	fixation	and	crystal	violet	staining.	Images	
of	 duplicate	 inserts	were	 acquired	on	 an	Olympus	BX-	51	micro-
scope.	Migration	was	 quantified	 by	 using	 the	 Fiji	 distribution	 of	
ImageJ	 as	 published	 before.27	 Data	 represent	 means	±	SD	 from	
three	 independent	 experiments	 performed	 with	 three	 different	
cell	donors,	each	in	triplicates.
2.5 | qRT- PCR
Quantitative	 RT-	PCR	 was	 used	 to	 investigate	 the	 expression	 of	
COL1A1,	COL3A1,	TGFB1,	TGFB3,	PDGFB,	FGF2,	EGF,	IL1A,	IL1B,	
TNF,	MMP1,	2,	3,	and	8	genes.	Total	RNA	from	HA-	or	growth	factor-	
treated	cells	was	isolated	using	the	RNeasy	Mini	Kit	(Qiagen,	Basel,	
Switzerland).	RNA	was	reverse	transcribed	and	relative	transcripts	
for	 the	above	genes,	normalized	 to	GAPDH,	were	measured	using	
FastStart	Universal	SYBR	Green	Master	ROX	(Roche)	and	the	primer	
sequences	listed	in	Table	S1.	Real-	time	PCR	was	carried	out	in	a	7500	
Real-	Time	PCR	System	(Applied	Biosystems,	Foster	City,	CA,	USA).	
Data	were	analyzed	using	the	efficiency	∆∆Ct	method.29	All	samples	
were	 run	 in	duplicates.	Data	 represent	means	±	SD	 from	 three	 in-
dependent	experiments	performed	with	three	different	cell	donors.
2.6 | Immunoblotting
Whole-	cell	extracts	from	HA-	treated	HPF	and	HGF	cells	were	pre-
pared	 by	 lysis	 in	RIPA	buffer	 as	 described.30	 Lysates	were	 run	 on	
10%	SDS-	PAGE,	and	transferred	to	Amersham™	Protran® membrane 
(Sigma,	Basel,	Switzerland).	Proteins	of	interest	were	visualized	using	
anti-	phospho-	Akt,	 anti-	Akt,	 anti-	phospho-	Erk1/2,	 anti-	Erk,	 anti-	
phospho-	p38,	anti-	p38	(all	from	Cell	Signaling	Technology,	Danvers,	
MA,	USA),	and	anti-	vinculin	(Sigma)	antibodies	followed	by	horserad-
ish	 peroxidase-	conjugated	 secondary	 antibodies	 (MP	 Biomedicals,	
Santa	Ana,	CA,	USA)	for	detection	with	the	SuperSignal™	West	Dura	
Substrate	 (ThermoFisher	 Scientific,	 Zug,	 Switzerland).	 Phospho-	
Akt,	 phospho-	Erk1/2	 or	 phospho-	p38	 protein	 expression	 relative	
to	 the	 respective	 total	 protein	 control	 was	 quantified	 by	 densi-
tometry	 using	 ImageQuant	 (Molecular	 Dynamics,	 Groningen,	 The	
Netherlands).	Data	 represent	means	±	SD	 from	 three	 independent	
experiments	performed	with	three	different	cell	donors.
2.7 | Statistical analysis
All	grouped	data	are	means	±	SD.	Differences	between	groups	were	
assessed	by	one-	way	analysis	of	variance	(ANOVA)	with	Tukey’s	post	
hoc	 test	 using	GraphPad	 InStat	 Software,	 version	 3.05.	 Values	 of	
P	<	0.05	were	considered	statistically	significant.
3  | RESULTS
3.1 | The two HA preparations exert no negative 
effects on the viability of primary HPF and HGF cells
Coating	of	cell	culture	plates	with	HA1	resulted	in	the	formation	
of	a	continuous	uniform	gel	layer	onto	which	both	cell	types,	HPF	
and	HGF,	were	able	 to	adhere	and	assumed	a	 fibroblast-	specific	
spindle-	shaped	morphology	that	did	not	differ	from	the	morphol-
ogy	of	 untreated	 cells	 seeded	on	non-	coated	 cell	 culture	 plastic	
(Figure	S1).	 In	contrast,	 coating	with	HA2	resulted	 in	 the	 forma-
tion	of	HA	meshes,	most	 likely	due	to	HA2	being	cross-	linked	to	
BDDE.	 Thus,	 cells	 appeared	 to	 adhere	 solely	 on	 the	 cell	 culture	
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plastic	while	HA2	was	present	 in	 suspension	 (Figure	S1).	Due	 to	
the	observed	difference	in	the	natural	occurrence	of	the	two	HAs,	
a	further	distinction	between	HA	applied	as	a	coating	or	in	suspen-
sion	was	not	made	and	we	referred	to	“HA	treatment”	throughout	
the	study.
We	 first	 compared	 the	effects	of	 the	 two	HA	preparations	on	
HPF	and	HGF	cell	viability.	Relative	 to	control	 cells	 (0	mg/mL	HA;	
100%	cell	viability),	 fibroblasts	exposed	to	HA1	or	HA2	at	various	
concentrations	 (0-	4	mg/mL)	 maintained	 a	 high	 level	 of	 viability	
(≥100%;	Figure	1A).
F IGURE  1 Effects	of	hyaluronan	(HA)	preparations	on	the	metabolism	and	behavior	of	primary	human	palatal	(HPF)	and	gingival	(HGF)	
fibroblasts.	A,	The	two	HA	preparations	exert	no	negative	effects	on	the	viability	of	primary	oral	fibroblasts.	Viability	of	HPF	and	HGF	cells	
incubated	with	various	concentrations	(0-	4	mg/mL)	of	each	of	the	two	HA	preparations	was	assessed	by	measuring	the	metabolic	capacity	
using	the	CellTiter-	Blue®	Cell	Viability	Assay.	Viable	cells	retain	the	ability	to	reduce	the	indicator	dye	resazurin	into	highly	fluorescent	
resorufin.	Experimental	values	were	normalized	to	those	of	control	cells	(0	mg/mL	HA;	100%	viability).	Data	represent	means	±	SD	from	
three	independent	experiments.	B	and	C,	The	two	HA	preparations	strongly	increase	the	proliferative	and	migratory	abilities	of	primary	
oral	fibroblasts.	B,	Proliferation	rates	of	HA-	treated	HPF	and	HGF	cells	were	assessed	by	BrdU	incorporation	into	newly	synthesized	DNA	
immediately	after	plating	(0	h)	as	well	as	at	24,	48,	72,	and	96	h.	Means	±	SD	from	three	independent	experiments	and	significant	differences	
to	control	(ctrl)	cells	at	the	time	point	0,	***P	<	0.001,	**P	<	0.01	are	shown.	C,	Migration	of	HPF	and	HGF	cells	toward	HA	was	evaluated	by	
transwell	migration	assay	using	filters	with	8	μm	pore	size.	Cell	migration	was	quantified	by	measuring	the	area	on	the	lower	side	of	the	filter	
covered	with	cells.	Means	±	SD	from	three	independent	experiments	and	significant	differences	to	control	cells,	***P	<	0.001,	**P	<	0.01	are	
shown.	Representative	images	of	the	staining	in	each	of	the	experimental	groups	are	shown	below	the	bar	graph.	Scale	bar,	500	μm
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3.2 | The two HA preparations strongly increase the 
proliferative and migratory abilities of primary 
HPF and HGF cells
Next,	we	assessed	the	effects	of	the	two	HA	preparations	on	the	
proliferation	 rates	of	HPF	and	HGF	cells	 (Figure	1B).	Compared	
to	untreated	control	cells,	HPF	cells	 treated	with	either	HA1	or	
HA2	 showed	 a	 significant	 increase	 in	 BrdU	 uptake	 into	 newly	
synthesized	 DNA	 until	 they	 reached	 confluence	 72	hours	 later	
(Figure	1B,	 left	 panel).	 In	 contrast,	 HGF	 cells	 exposed	 to	 each	
of	 the	 two	HAs	 behaved	 like	 control	 cells	 in	 the	 first	 24	hours	
(Figure	1B,	 right	 panel).	 Thereafter,	 they	 showed	 a	 significant	
increase	in	BrdU	uptake	until	they	reached	confluence	48	hours	
later.	Compared	to	HA1,	the	pro-	proliferative	effect	of	HA2	ap-
peared	 to	be	slightly	more	pronounced	 in	both	cell	 types,	but	a	
significant	difference	(P	<	0.01)	in	the	activity	of	the	two	HAs	was	
only	 detected	 in	HPF	 cells	 48	hours	 post	 treatment	 (Figure	1B,	
left	panel).
F IGURE  2 The	two	hyaluronan	
(HA)	preparations	trigger	expression	of	
COL3A1	and	TGFB3	genes	characterizing	
scarless	wound	healing.	Effect	of	HA1	and	
HA2	on	COL1A1	(A),	COL3A1	(B),	TGFB1	
(C),	and	TGFB3	(D)	mRNA	levels	in	primary	
human	palatal	(HPF)	and	gingival	(HGF)	
fibroblasts.	Oral	fibroblasts	were	treated	
with	each	of	the	two	HA	preparations	for	
24	h	before	total	RNA	was	extracted	and	
analyzed	by	qRT-	PCR.	Values	normalized	
to	GAPDH	are	expressed	relative	to	the	
values	of	untreated	control	(ctrl)	cells.	
Data	represent	means	±	SD	from	three	
independent	experiments.	Significant	
differences	to	the	respective	control	
unless	otherwise	indicated,	***P	<	0.001,	
**P	<	0.01,	*P	<	0.05
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Next,	 we	 examined	 the	 migratory	 capacity	 of	 oral	 fibroblasts	
toward	HA	using	a	transwell	assay.	Similarly	to	the	effect	on	cellu-
lar	proliferation,	each	of	 the	 two	HA	preparations	 significantly	 in-
duced	fibroblast	cell	migration	by	6-	9-	fold	compared	to	control	cells	
(P	<	0.01;	Figure	1C).
Taken	together,	these	results	showed	a	strong	pro-	proliferative	and	
pro-	migratory	effect	of	HA	on	primary	oral	fibroblasts	with	no	signifi-
cant	differences	in	the	potency	between	the	two	HA	formulations.
3.3 | The two HA preparations trigger expression of 
COL3A1 and TGFB3 genes characterizing scarless 
wound healing
Invasion	and	proliferation	of	fibroblasts	at	the	defect	site	precedes	
collagen	 deposition.	 Thus,	 we	 next	 studied	 the	 effect	 of	 the	 HA	
preparations	 on	 the	 expression	 of	 type	 I	 and	 type	 III	 collagens	 in	
the	primary	oral	fibroblasts	(Figure	2A	and	B).	Accumulation	of	type	
I	collagen	 is	enhanced	 in	scars	and	fibrosis,	whereas	type	 III	colla-
gen	is	abundant	during	fetal	development	and	scarless	fetal	wound	
healing.31	 Interestingly,	compared	to	untreated	control	cells,	either	
HA	 preparation	 upregulated	 the	 expression	 levels	 of	 COL3A1	 in	
both	HPFs	and	HGFs	at	24	hour	 (Figure	2B),	whereas	no	effect	on	
COL1A1	mRNA	levels	was	detected	(Figure	2A).
We	 further	 determined	 the	 influence	 of	 the	HA	preparations	
on	 the	 expression	 of	 TGFB1	 and	 TGFB3	 (Figure	2C	 and	 D),	 two	
TGF-	β	 isoforms	 that	play	 critical	 roles	 in	wound	healing	by	mod-
ulating	 ECM	 formation.	 Whereas	 TGF-	β1	 is	 generally	 known	 as	
pro-	fibrotic,	 TGF-	β3	 is	 the	 isoform	 that	 predominates	 in	 scarless	
fetal	wound	healing.32	Interestingly,	both	HAs	caused	a	significant	
increase	 in	 TGFB3	mRNA	 levels	 compared	 to	 control	 fibroblasts	
F IGURE  3 Hyaluronan	(HA)	induces	expression	of	genes	encoding	growth	factors	and	cytokines	essential	for	the	wound	healing	process	
in	primary	human	palatal	(HPF)	and	gingival	(HGF)	fibroblasts.	Effect	of	HA1	and	HA2	on	PDGFB	(A),	FGF2	(B),		EGF	(C),	IL1A	(D),	IL1B	(E),	
and	TNF	(F)	mRNA	levels	in	HPF	and	HGF	cells.	Oral	fibroblasts	were	treated	with	each	of	the	two	HA	preparations	for	24	h	before	total	
RNA	was	extracted	and	analyzed	by	qRT-	PCR.	Values	normalized	to	GAPDH	are	expressed	relative	to	the	values	of	untreated	control	(ctrl)	
cells.	Data	represent	means	±	SD	from	three	independent	experiments.	Significant	differences	to	the	respective	control	unless	otherwise	
indicated,	***P	<	0.001,	**P	<	0.01,	*P	<	0.05
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(Figure	2D),	 whereas	 the	 expression	 of	 TGFB1	 was	 unchanged	
(Figure	2C).	Furthermore,	 in	both	cell	 types,	HA1	appeared	 to	be	
more	potent	(by	2-	fold,	P	<	0.001)	than	HA2	in	inducing	TGFB3	ex-
pression	(Figure	2D).
These	 results	 indicated	 that	both	HAs	 favor	 the	expression	of	
genes	characteristic	of	scarless	vs	pro-	fibrotic	wound	healing.
3.4 | HA induces expression of genes encoding 
growth factors and cytokines involved in wound 
healing in primary HPF and HGF cells
Growth	factors	such	as	PDGFB,	FGF-	2	and	EGF	stimulate	the	pro-
liferation	 and	 migration	 of	 human	 gingival	 fibroblasts	 in	 a	 dose-	
dependent	manner.33,34	Thus,	we	investigated	if	the	HA	formulations	
might	affect	cellular	proliferation	and	migration	through	influencing	
the	expression	of	these	growth	factors.	qRT-	PCR	analyses	revealed	
a	significant	induction	of	all	three	growth	factors	in	both	HPFs	and	
HGFs	exposed	to	each	of	the	two	HAs	compared	to	basal	expres-
sion	 levels	 in	control	cells	 (Figure	3A-	C).	 In	 isolated	cases,	one	HA	
appeared	to	be	more	potent	than	the	other,	eg,	HA1	caused	a	sig-
nificantly	higher	induction	of	PDGFB	mRNA	in	HGF	cells	(Figure	3A,	
right	panel),	whereas	HA2	more	strongly	induced	FGF2	expression	
in	HPF	cells	(Figure	3B,	left	panel).
We	next	examined	the	effect	of	the	two	HAs	on	the	expres-
sion	of	the	pro-	inflammatory	cytokine	genes	IL1A,	IL1B	and	TNF	
(Figure	3D-	F).	Similarly	to	the	effect	on	growth	factor	expression,	
both	HAs	 caused	 a	 significant	 upregulation	 of	mRNA	 levels	 for	
each	cytokine	in	both	HPFs	and	HGFs.	A	slightly	but	significantly	
higher	 induction	of	 IL1A	expression	was	 triggered	by	HA1	com-
pared	to	HA2	 in	HPFs	 (Figure	3D,	 left	panel).	 Interestingly,	both	
HAs	appeared	to	stimulate	pro-	inflammatory	cytokine	expression	
more	potently	in	HPF	compared	to	HGF	cells	(Figure	3D-	F,	com-
pare	left	with	right	panels).	The	comparison	between	the	two	cell	
types	was	possible	based	on	 (a)	 identical	basal	expression	 levels	
for	 each	 of	 the	 three	mRNAs	 encoding	 pro-	inflammatory	 cyto-
kines	 in	 control	 HPFs	 and	 HGFs	 (Ctctrl	=	33	 for	 IL1A;	 Ctctrl	= 30 
for	IL1B,	and	Ctctrl	=	31	for	TNF)	and	(b)	identical	endogenous	HA	
expression	 levels	 in	 culture	 supernatants	 of	 the	 two	 cell	 types	
(Figure	S2).
In	 summary,	 the	 two	 HA	 preparations	 caused	 upregulation	 of	
wound	healing-	related	growth	factors	and	cytokines	in	primary	oral	
fibroblasts,	with	a	more	moderate	effect	on	pro-	inflammatory	cyto-
kine	expression	in	gingival	compared	to	palatal	fibroblasts.	No	clear	
trend	for	a	difference	in	efficacy	between	the	two	HA	formulations	
was	observed.
3.5 | HA induces cell type- specific differences in the 
expression of MMP2 and MMP3 genes
During	oral	wound	healing,	the	granulation	tissue	ECM	is	continu-
ously	 remodeled	 by	 MMPs,	 most	 notably	 collagenases	 MMP-	1	
and	 8,	 major	 gelatinase	 MMP-	2,	 and	 stromelysin-	1	 (MMP-	3).35 
qRT-	PCR	analyses	revealed	that	treatment	of	both	cell	types	with	
HAs	 resulted	 in	 an	 increase	 in	MMP1	 and	MMP8	mRNA	 levels	
above	those	obtained	in	control	cells	(Figure	4A	and	B).	Whereas	
HA2	appeared	to	be	slightly	more	potent	than	HA1	for	induction	
of	MMP1	 in	both	HPF	and	HGF	cells	 (Figure	4A),	HA1	caused	a	
higher	 expression	 of	MMP8	 than	HA2	 in	HPFs	 only	 (Figure	4B,	
left	 panel).	 Interestingly,	 we	 observed	 a	 significant	 induction	
of	 MMP2	 mRNA	 levels	 in	 HA-	treated	 HPF	 but	 not	 HGF	 cells	
(Figure	4C),	despite	the	facts	that	 (a)	MMP2	is	constitutively	ex-
pressed	by	mucosal	 fibroblasts36	 and	 (b)	 basal	 expression	 levels	
of	MMP2	were	 the	 same	 in	 control	HPF	and	HGF	cells,	 respec-
tively	(Ctctrl	=	20).	Furthermore,	at	identical	basal	expression	lev-
els	(Ctctrl	=	24)	in	control	cells	of	both	types,	a	3-	5-	fold	induction	
was	evident	for	MMP3	upon	HA	treatment	of	HPF	but	not	HGF	
cells	(Figure	4D).
Thus,	we	observed	cell	type-	specific	differences	in	the	expres-
sion	of	two	of	the	four	MMPs	tested	upon	HA	treatment.
3.6 | Pro- inflammatory cytokines exhibit a 
stimulatory and dose- dependent effect on MMP2 and 
MMP3 gene expression in primary HPF and HGF cells
The	pro-	inflammatory	cytokines	IL-	1α,	 IL-	1β,	and	TNF-	α	are	known	
to	play	a	major	role	in	regulating	MMP	expression	in	different	fibro-
blast	cell	lines	and	inflammatory	diseases.35	To	investigate	the	mech-
anism	behind	the	differential	induction	of	MMP2	and	MMP3	by	HA	
in	HPF	vs	HGF	cells,	we	treated	oral	 fibroblasts	with	recombinant	
pro-	inflammatory	cytokines	and	examined	 the	effect	on	MMP	ex-
pression.	qRT-	PCR	analyses	revealed	that	increasing	concentrations	
(5	and	10	ng/mL)	of	IL-	1α,	IL-	1β,	or	TNF-	α	applied	to	HPF	or	HGF	cells	
had	no	effect	on	the	expression	of	MMP1	and	MMP8	mRNA	levels	
(Figure	5A	and	B)	but	caused	a	significant	and	dose-	dependent	 in-
crease	in	MMP2	and	MMP3	mRNAs	(Figure	5C	and	D)	compared	to	
their	levels	in	untreated	cells.	This	suggests	that	whereas	HA	might	
independently	 influence	 MMP1	 and	 MMP8	 gene	 expression	 (cf.	
Figure	4A,	B),	the	effect	of	HA	on	MMP2	and	MMP3	expression	in	
HPF	and	HGF	cells	appears	to	occur	indirectly	and	reflects	the	HA-	
induced	 expression	 of	 pro-	inflammatory	 cytokines	 (cf.	 Figures	4C,	
D	and	3D-	F).
3.7 | The two HA preparations significantly enhance 
phosphorylation of Akt, Erk1/2 and p38 kinases in 
primary oral fibroblasts
To	gain	insights	into	the	mechanisms	whereby	the	two	HAs	exert	their	
effects	on	gene	expression	in	primary	oral	fibroblasts,	we	investigated	
the	activation	state	of	signaling	kinases	that	might	be	triggered	by	HA.	
We	 focused	 on	 the	 activation	 of	 PI3-	kinase/Akt,	 Erk1/2,	 and	 p38,	
because	HA	has	been	reported	to	stimulate	these	pathways	in	other	
systems.9	 Compared	 to	 the	 basal	 levels	 of	 phospho-	Akt,	 phospho-	
Erk1/2,	and	phospho-	p38	detected	 in	control	cells,	phosphorylation	
of	each	of	the	three	kinases	significantly	increased	in	both	HPFs	and	
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HGFs	treated	with	either	HA	formulation	for	30	minutes	(Figure	6).	In	
particular,	the	phosphorylation	of	Akt	in	HA-	treated	cells	was	upregu-
lated	between	3.7	and	5.4-	fold	compared	to	control	cells	(Figure	6A),	
whereas	the	phosphorylation	of	Erk1/2	and	p38	increased	by	2.3-	4.3-	
and	2.8-	4.2-	fold,	respectively	(Figure	6B	and	C).
These	results	indicated	that	each	of	the	two	HA	formulations	was	
able	to	trigger	downstream	signaling	events	through	activation	of	Akt,	
Erk1/2,	or	p38	kinases	in	primary	oral	fibroblasts.	No	trend	for	a	more	
pronounced	effect	 of	 one	or	 the	other	HA	on	 the	 activation	of	 the	
three	signaling	pathways	was	observed.
F IGURE  4 Hyaluronan	(HA)	induces	
cell	type-	specific	differences	in	the	
expression	of	MMP2	and	MMP3	genes.	
Effect	of	HA1	and	HA2	on	MMP1	(A),	
MMP8	(B),	MMP2	(C),	and	MMP3	(D)	
mRNA	levels	in	primary	human	palatal	
(HPF)	and	gingival	(HGF)	fibroblasts.	
Oral	fibroblasts	were	treated	with	each	
of	the	two	HA	preparations	for	24	h	
before	total	RNA	was	extracted	and	
analyzed	by	qRT-	PCR.	Values	normalized	
to	GAPDH	are	expressed	relative	to	the	
values	of	untreated	control	(ctrl)	cells.	
Data	represent	means	±	SD	from	three	
independent	experiments.	Significant	
differences	to	the	respective	control	
unless	otherwise	indicated,	***P	<	0.001,	
**P	<	0.01,	*P	<	0.05
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4  | DISCUSSION
Palatal	and	gingival	fibroblasts	play	an	important	role	in	oral	wound	
healing.	 The	 use	 of	 bioactive	 substances	 that	 influence	 their	
behavior	and	thus	support	oral	soft	tissue	wound	healing/regen-
eration	is	of	major	clinical	interest.	Therefore,	the	aim	of	the	pre-
sent	study	was	to	investigate	the	specific	role	of	two	commercially	
available	HA	formulations	in	affecting	oral	fibroblast	cell	behavior,	
F IGURE  5 Pro-	inflammatory	cytokines	exhibit	a	stimulatory	and	dose-	dependent	effect	on	MMP2	and	MMP3	gene	expression	in	
primary	human	oral	fibroblasts.	Effect	of	recombinant	IL-	1α,	IL-	1β,	andTNF-	α	on	the	expression	of	MMP	genes	in	primary	human	palatal	
(HPF)	and	gingival	(HGF)	fibroblasts.	Cells	were	treated	with	increasing	concentrations	(0,	5,	and	10	ng/mL)	of	each	of	the	three	pro-	
inflammatory	cytokines	for	24	h	before	total	RNA	was	extracted.	Expression	of	MMP1	(A),	MMP8	(B),	MMP2	(C),	and	MMP3	(D)	mRNAs	was	
analyzed	by	qRT-	PCR.	Values	normalized	to	GAPDH	are	expressed	relative	to	the	values	of	untreated	cells	(0	ng/mL	HA).	Means	±	SD	from	
three	independent	experiments	and	significant	differences	to	untreated	cells,	***P	<	0.001,	**P	<	0.01,	*P	<	0.05	are	shown
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including	proliferation,	migration,	and	wound	healing-	related	gene	
expression.	All	these	processes	affect	soft	tissue	wound	healing/
regeneration	 following	 reconstructive	 periodontal	 surgery.	 Our	
data	demonstrate	 that	both	 formulations	of	HA	 (a)	are	 fully	bio-
compatible	and	exert	no	negative	effects	on	the	viability	of	HPFs	
and	 HGFs;	 (b)	 are	 able	 to	 increase	 the	 proliferative	 and	 migra-
tory	abilities	of	both	cell	types;	(c)	trigger	expression	of	COL3A1	
and	TGFB3	genes	characterizing	scarless	fetal	wound	healing;	(d)	
upregulate	 the	expression	of	genes	encoding	the	growth	factors	
PDGFB,	FGF-	2,	and	EGF,	which	are	essential	for	the	wound	heal-
ing	 process;	 (e)	 induce	 pro-	inflammatory	 cytokine	 gene	 expres-
sion,	 thus	potentially	 initiating	 a	 cellular	 inflammatory	 response;	
and	(f)	affect	MMP	gene	expression	either	directly	(MMP1	and	8)	
or	indirectly	(MMP2	and	3),	potentially	through	induction	of	pro-	
inflammatory	cytokines,	thus	influencing	ECM	remodeling.	Finally,	
(g)	our	data	point	on	Akt,	Erk1/2,	and	p38	as	the	signaling	mole-
cules	by	which	the	two	HA	preparations	exert	their	effects	on	oral	
fibroblasts.	 Understanding	 the	mechanisms	whereby	 these	 HAs	
function	may	reveal	how	to	 intervene	 in	 the	dynamic	process	of	
oral	soft	tissue	regeneration	with	the	aim	to	improve	it.
The	 investigated	 HA	 preparations	 appear	 close	 to	 the	 phys-
iological	 HA	 that	 is	 found	 in	 many	 biological	 fluids	 and	 solid	 tis-
sues	and	 is	 reported	 to	possess	an	average	MW	of	approximately	
1000-	6000	kDa.37	 Little	 if	 any	 HA	 below	 1000	kDa	 is	 found	 in	
healthy	 solid	 tissues.37	 On	 the	 other	 hand,	 human	 amniotic	 fluid	
contains	 HA	 with	 an	 average	 MW	 of	 approximately	 330	kDa	 at	
16	weeks	gestation	and	is	characterized	with	a	change	to	a	mixture	
of	high	and	very	 low	MW	HA	by	40	weeks	gestation.38	The	main-
tained	high	viability	of	HA-	treated	fibroblasts	in	our	study	might	be	
due	to	the	physiochemical	properties	of	high	MW	HA	that	is	shown	
to	exhibit	an	optimal	viscoelasticity,	prolonged	dwell	 time,	and	ex-
tended	biocompatibility.39	Favorable	effects	on	viability	of	odonto-
blasts,	 fibroblasts,	 and	periodontal	 ligament	 (PDL)	 cells	have	been	
reported	 previously	 with	 other	 HA	 formulations.40,41	 The	 cross-	
linking	 to	BDDE,	which	 characterizes	 one	of	 our	HA	 formulations	
(HA2),	 did	 not	 seem	 to	 negatively	 influence	 cell	 viability	 as	 also	
shown	by	others.42
The	 effect	 of	 HA	 on	 cell	 proliferation	 in	 vitro	 is	 known	 to	 be	
closely	 related	 to	 its	MW	and	 concentration.22	 Low	MW	HA	was	
reported	to	increase	cell	proliferation	in	studies	with	rat	and	mouse	
mesenchymal	 stem	 cells,43,44	 rabbit	 bone	 marrow-	derived	 stem	
cells45	as	well	as	in	an	organotypic	keratinocyte-	fibroblast	co-	culture	
model.46	In	contrast,	the	reported	effects	of	high	MW	HA	on	cellular	
proliferation	are	controversial.22	A	significant	stimulatory	as	well	as	
an	inhibitory	effect	has	been	seen	dependent	on	the	cellular	context,	
HA	concentrations,	and	method	of	delivery	of	HA	to	the	cell	culture.	
F IGURE  6 The	two	hyaluronan	
(HA)	preparations	significantly	enhance	
phosphorylation	of	Akt,	Erk1/2,	and	p38	
kinases	in	primary	human	oral	fibroblasts.	
Immunoblot	analyses	of	phospho-	Akt	
(pAkt)	(A),	phospho-	Erk1/2	(pErk1/2)	
(B),	and	phospho-	p38	(pp38)	(C)	proteins	
in	whole-	cell	extracts	from	HA-	treated	
primary	human	palatal	(HPF)	and	gingival	
(HGF)	fibroblasts.	Blots	for	total	Akt,	
Erk1/2,	and	p38	proteins	as	well	as	the	
vinculin	loading	control	are	also	shown.	
The	bar	charts	represent	densitometric	
quantifications	of	the	immunoblots.	pAkt,	
pErk1/2,	and	pp38	levels	are	normalized	
to	the	respective	total	proteins	used	
as	internal	controls.	Data	represent	
means	±	SD	from	three	independent	
experiments.	Significant	differences	to	the	
respective	control	(ctrl)	cells	of	each	of	the	
two	cell	types,	**P	<	0.01,	*P	<	0.05
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Here,	we	report	a	strong	positive	effect	of	both	HA	preparations	on	
HPF	and	HGF	cell	proliferation.	In	addition	to	the	pro-	proliferative	
effect,	we	observed	a	significantly	enhanced	migratory	ability	of	oral	
fibroblasts	toward	HA.	The	HA-	induced	cell	motility	might	be	due	to	
enhanced	Erk	phosphorylation	caused	by	the	exogenous	application	
of	HA	 on	 oral	 fibroblasts	 that	we	 have	 detected.	 Consistent	with	
our	 findings,	 several	groups	have	shown	that	HA	activates	Erk1,47 
PI3K-	Akt,48	and	p3849	signaling	pathways	that	promote	cell	survival,	
motility,	and	proliferation.	In	accordance	with	those	studies,	the	two	
HA	formulations	caused	statistically	 significant	 induction	of	genes	
encoding	 pro-	proliferative	 and	 pro-	migratory	 growth	 factors	 such	
as	PDGFB,	FGF-	2,	and	EGF.	Furthermore,	once	upregulated	at	the	
defect	 site,	 these	 factors	might	 themselves	 stimulate	 synthesis	 of	
endogenous	HA,	as	all	three	of	them	have	been	shown	to	enhance	
mRNA	expression	for	specific	HA	synthases.50,51	Future	research	is	
needed	to	 identify	the	receptors	that	might	be	responsible	for	the	
observed	effects	of	the	two	HA	formulations	on	the	behavior	of	oral	
fibroblasts.	It	is	well	known	that	native	HA	can	bind	to	specific	cell	
surface	receptors	such	as	CD44,	RHAMM	(receptor	for	hyaluronan-	
mediated	motility	 expressed	 protein),	 or	 LYVE-	1	 (lymphatic	 vessel	
endothelial	 hyaluronan	 receptor-	1),	 thus	 inducing	 transduction	 of	
intracellular	signals	influencing	cell	survival,	proliferation,	and	motil-
ity.52	Earlier	research	by	Hirano	et	al53	have	shown	that	periodontal	
tissues,	in	particular	human	gingival	fibroblasts,	human	periodontal	
ligament	 fibroblasts,	and	human	gingival	epithelial	cells	all	express	
CD44	protein	and	its	mRNA.	Furthermore,	 it	has	been	shown	that	
interaction	between	CD44	and	other	 receptors	 such	as	epidermal	
growth	 factor	 receptor	 (EGFR)	 are	 essential	 for	 modulating	 HA-	
dependent	fibroblast	proliferation.54
The	 high	 abundance	 of	 HA	 in	 amniotic	 fluid	 and	 embryonic	
tissues	and	 its	 involvement	 in	a	mechanism	 that	 supports	 scarless	
repair	 in	 the	 fetus	are	well	documented.55	Here,	we	report	an	up-
regulation	 of	 COL3A1	 and	 TGFB3	 gene	 expression	 in	HA-	treated	
oral	fibroblasts,	suggesting	that	the	HAs	tested	in	our	study	might	
contribute	to	the	generation	of	a	fetal-	like	cell	environment	that	fa-
vors	scarless	healing.	Thus,	HA	might	appear	particularly	important	
in	the	early	stages	of	wound	repair	when	ECM	deposition	needs	to	
be	limited.
Exogenous	 high	 MW-	HA	 has	 been	 shown	 to	 be	 anti-	
inflammatory,	eg,	in	a	T	cell-	mediated	liver	injury	model	in	mice56 
or	 in	 fibroblast-	like	 synoviocytes	 in	 a	 human	 osteoarthritis	
model.57	 On	 contrary,	 we	 observed	 an	 increased	 expression	 of	
pro-	inflammatory	cytokines	in	oral	fibroblasts	treated	with	each	of	
the	two	high	MW-	HAs.	Others	have	also	shown	that	high	MW-	HA	
stimulates	production	of	 IL-	1β,	TNF-	α,	and	 IL-	8	 in	human	uterine	
fibroblasts.12	These	contradictions	might	be	related	to	the	specific	
HA	 formulations	 as	 well	 as	 the	 cellular	 context	 used.	 However,	
as	 an	 inflammatory	 reaction	 is	 generally	 indispensable	 for	 the	
kick-	off	of	wound	 repair,	 the	pro-	inflammatory	effect	of	 the	HA	
preparations	 tested	 in	 the	 current	 study	might	 appear	 clinically	
beneficial	 especially	when	 the	HAs	 are	 applied	on	non-	inflamed	
tissues	during	plastic-	esthetic	periodontal	 surgery.	 Furthermore,	
it	has	been	shown	that	the	pro-	inflammatory	cytokines	IL-	1α,	IL-	1β,	
and	TNF-	α	play	a	major	role	in	regulating	MMP	expression	in	dif-
ferent	cell	types.35,58-63	The	effects	of	the	pro-	inflammatory	cyto-
kines	on	MMP	expression	appear	to	depend	greatly	on	the	cellular	
context.	It	has	been	reported	that	IL-	1α	upregulates	MMP1	and	3	
mRNA	and	protein	expression	 in	dental	pulp	fibroblasts,	thus	 in-
ducing	collagen	degradation	and	pulp	destruction.60	Furthermore,	
expression	of	MMP1,	2,	and	3	in	dental	pulp	fibroblasts	was	also	
stimulated	by	IL-	1β	and	TNF-	α.59	In	contrast,	Dasu	and	colleagues	
have	 shown	 that	 MMP-	1	 mRNA	 expression	 was	 markedly	 in-
creased	with	 IL-	6	and	TNF-	α	 treatment	but	remained	unchanged	
with	IL-	1β	in	the	context	of	human	dermal	fibroblasts.62	In	our	sys-
tem,	treatment	with	each	of	the	three	pro-	inflammatory	cytokines	
caused	a	significant	 increase	 in	MMP2	and	3	transcripts	but	had	
no	influence	on	MMP1	and	8,	suggesting	that	the	effect	of	HA	on	
the	expression	of	MMP2	and	3	in	oral	fibroblasts	is	indirect	and	re-
flects	the	HA-	induced	expression	of	pro-	inflammatory	cytokines.	
Both,	prolonged	 inflammation	as	well	as	an	excessive	amount	of	
MMPs	acting	 for	 a	 long	 time	on	 the	healing	 tissue,	 are	deleteri-
ous	for	the	wound	healing	process.	 In	this	respect,	the	observed	
indirect	effect	on	the	expression	of	MMP2	and	MMP3,	as	well	as	
the	moderate	 induction	of	 pro-	inflammatory	 cytokines	 in	HGFs,	
suggests	 that	 the	 investigated	HA	 formulations	 are	 not	 likely	 to	
contribute	to	deleterious	effects	on	the	wound	healing	process.
Naturally,	our	in	vitro	experiments	have	certain	limitations	that	
can	only	be	addressed	by	in	vivo	studies.	Cross-	linking	of	bioactive	
substances	aims	to	increase	their	rheological	stability	at	the	site	of	
injury.	However,	the	effect	of	cross-	linking	might	only	be	apparent	
in	vivo	as	in	vitro	experiments	are	too	short-	term	to	allow	an	effect	
on	stability	to	become	obvious.	Furthermore,	both	HA	preparations	
tested	in	our	study	are	considered	high	MW.	However,	in	vivo	these	
HAs	would	undergo	degradation	to	lower	MW	molecules	following	
hyaluronidase	activity	during	the	postoperative	period,	eg,	after	root	
coverage,	implant	placement	or	sinus	lift	surgery,	and	will	thus	exert	
additional	 or	 even	 opposing	 effects	 on	 the	 regenerative	 process.	
Despite	these	clear	limitations,	the	obtained	in	vitro	results	contrib-
ute	to	understanding	the	complexity	of	the	wound	healing	process,	
as	well	as	the	clinical	potential	of	the	two	hyaluronan	preparations	
for	oral	soft	tissue	regeneration.
In	conclusion,	both	HA	formulations	investigated	in	the	current	
study	exert	diverse	positive	effects	on	human	palatal	and	gingival	
fibroblasts,	 two	cell	 types	 involved	 in	soft	 tissue	 regeneration	 fol-
lowing	periodontal	reconstructive	therapies	that	utilize	palatal	con-
nective	tissue	or	free	gingival	grafts.	The	observed	pro-	proliferative,	
pro-	migratory	 and	 pro-	wound	 healing	 properties	 of	 the	 two	 HAs	
speak	 in	 favor	of	 their	clinical	potential.	However,	animal	 research	
and/or	clinical	randomized	controlled	trials	with	long-	term	follow-	up	
studies	are	needed	to	evaluate	the	clinical	efficacy	of	the	two	HA	
preparations.
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